Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Lung cancer immunotherapy adjuvant and neoadjuvant indications
Dr. Luis Raez - Memorial Healthcare System, Florida, USA
Lung cancer immunotherapy adjuvant and neoadjuvant indications ( Dr. Luis Raez - Memorial Healthcare System, Florida, USA )
8 Jul 2022
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
28 Jun 2022
Study shows that there is slower cancer drug approval in Europe
Dr Mark Lythgoe - Imperial College London​​​​​, London, UK
Study shows that there is slower cancer drug approval in Europe ( Dr Mark Lythgoe - Imperial College London​​​​​, London, UK )
22 Jun 2022
ASCO and WHO to collaborate on quality indicators for cancer facilities
Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland
ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )
14 Jun 2022
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effe...
Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )
14 Jun 2022
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDM...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
Glofitamab induces durable complete remissions in patients with relapsed large B...
Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia
Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma ( Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia )
13 Jun 2022
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy i...
Prof Barbara Eichhorst - University of Cologne, Cologne, Germany
Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )
13 Jun 2022
Quizartinib advances overall survival in acute myeloid leukaemia patients
Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA
Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )
13 Jun 2022
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show...
Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodg...
Dr Paul Bröckelmann - University of Cologne, Cologne, Germany
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )
13 Jun 2022